Association between HLA class i and class ii alleles and the outcome of West Nile Virus infection: An exploratory study

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lanteri, Marion C ^a   Kaidarova, Zhanna ^a   Peterson, Trevor ^b   Cate, Steven ^c   Custer, Brian ^a,g,h   Wu, Shiquan ^a   Agapova, Maria ^a   Law, Jacqueline P ^a   Bielawny, Thomas ^b   Plummer, Frank ^b,e   Tobler, Leslie H ^a   Loeb, Mark ^d,f   Busch, Michael P ^a,h   Bramson, Jonathan ^d   Luo, Ma ^b,e   Norris, Philip J ^a,h  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; ASYMPTOMATIC DISEASE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HLA TYPING; HOST RANGE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; SYMPTOMATOLOGY; WEST NILE FEVER; COHORT ANALYSIS; GENETICS; PATHOPHYSIOLOGY; PHENOTYPE;

WEST NILE VIRUS;

ALLELES; COHORT STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; PHENOTYPE; WEST NILE FEVER;

EID: 79960961712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022948     Document Type: Article

References (66)

1. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, et al. (2001) Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358: 261-264.
2. Control CfD, (2010) West Nile virus activity- Human disease cases reported 2005-2010. Available:http://wwwcdcgov/ncidod/dvbid/westnile/.
3. Diamond MS, (2009) Progress on the development of therapeutics against West Nile virus. Antiviral Res 83: 214-227.
4. Diamond MS, Mehlhop E, Oliphant T, Samuel MA, (2009) The host immunologic response to West Nile encephalitis virus. Front Biosci 14: 3024-3034.
5. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, et al. (2004) Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10: 1366-1373.
6. Samuel MA, Diamond MS, (2006) Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80: 9349-9360.
7. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, et al. (2009) Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 119: 3266-3277.
8. Kumar D, Drebot MA, Wong SJ, Lim G, Artsob H, et al. (2004) A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant 4: 1883-1888.
9. Jean CM, Honarmand S, Louie JK, Glaser CA, (2007) Risk factors forWest Nile virus neuroinvasive disease, California, 2005. Emerg Infect Dis 13: 1918-1920.
10. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, et al. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203: 35-40.
11. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, et al. (2006) PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 80: 7009-7019.
12. Scherbik SV, Paranjape JM, Stockman BM, Silverman RH, Brinton MA, (2006) RNase L plays a role in the antiviral response to West Nile virus. J Virol 80: 2987-2999.
13. Lichtman AKAaAH, eds. (2005) Cellular and molecular Immunology. 5th ed Elsevier Saunders.
14. Schreuder GM, Hurley CK, Marsh SG, Lau M, Maiers M, et al. (2001) The HLA Dictionary 2001: a summary of HLA-A,-B,-C,-DRB1/3/4/5 and-DQB1 alleles and their association with serologically defined HLA-A,-B,-C,-DR and-DQ antigens. Eur J Immunogenet 28: 565-596.
15. Bade-Doeding C, Theodossis A, Gras S, Kjer-Nielsen L, Eiz-Vesper B, et al. (2010) The impact of human leucocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family. Haematologica 96: 110-118.
16. Axelsson-Robertson R, Ahmed RK, Weichold FF, Ehlers MM, Kock MM, et al. (2011) HLA-A*3001 and A*3002 show distinct peptide binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin Vaccine Immunol 18: 125-134.
17. Elamin NE, Bade-Doeding C, Blasczyk R, Eiz-Vesper B, (2010) Polymorphism between HLA-A*0301 and A*0302 located outside the pocket F alters the POmega peptide motif. Tissue Antigens 76: 487-490.
18. Wang P, Sidney J, Kim Y, Sette A, Lund O, et al. (2010) Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 11: 568.
19. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, et al. (2010) The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 464: 932-936.
20. Louie L, Ng S, Hajjeh R, Johnson R, Vugia D, et al. (1999) Influence of host genetics on the severity of coccidioidomycosis. Emerg Infect Dis 5: 672-680.
21. Hraber P, Kuiken C, Yusim K, (2007) Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 46: 1713-1721.
22. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, et al. (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41: 591-595.
23. Kuhn L, Abrams EJ, Palumbo P, Bulterys M, Aga R, et al. (2004) Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression. Aids 18: 1281-1289.
24. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, et al. (2006) Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43: 563-572.
25. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, et al. (2009) Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. Aids 23: 19-28.
26. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD, (2010) Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS One 5 doi:10.1371/journal.pone.0013029.
27. Falcon-Lezama JA, Ramos C, Zuniga J, Juarez-Palma L, Rangel-Flores H, et al. (2009) HLA class I and II polymorphisms in Mexican Mestizo patients with dengue fever. Acta Trop 112: 193-197.
28. LaFleur C, Granados J, Vargas-Alarcon G, Ruiz-Morales J, Villarreal-Garza C, et al. (2002) HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol 63: 1039-1044.
29. Nguyen TP, Kikuchi M, Vu TQ, Do QH, Tran TT, et al. (2008) Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2: e304.
30. Polizel JR, Bueno D, Visentainer JE, Sell AM, Borelli SD, et al. (2004) Association of human leukocyte antigen DQ1 and dengue fever in a white Southern Brazilian population. Mem Inst Oswaldo Cruz 99: 559-562.
31. Sierra B, Alegre R, Perez AB, Garcia G, Sturn-Ramirez K, et al. (2007) HLA-A,-B,-C, and-DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol 68: 531-540.
32. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, et al. (2002) HLA-A and-B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60: 309-318.
33. Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HA, et al. (2002) T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 168: 5959-5965.
34. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, et al. (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62: 1009-1030.
35. Piazza P, McMurtrey CP, Lelic A, Cook RL, Hess R, et al. (2010) Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One 5: e15343.
36. National Center for Biotechnology Information database for Major Histocompatibility Complex (NCBI dbMHC) Anthropology: The dbMHC database for DNA and clinical data related to the human Major Histocompatibility Complex. Available:http://www.ncbi.nlm.nih.gov/gv/mhc/ihwg.cgi?cmd=page&user_id=0&probe_id=0&source_id=0&locus_id=0&locus_group=1&proto_id=0&kit_id=0&page=AnthroMain.
37. Jupp PG, (2001) The ecology of West Nile virus in South Africa and the occurrence of outbreaks in humans. Ann N Y Acad Sci 951: 143-152.
38. Monini M, Falcone E, Busani L, Romi R, Ruggeri FM, (2010) West nile virus: characteristics of an african virus adapting to the third millennium world. Open Virol J 4: 42-51.
39. Depoortere E, Kavle J, Keus K, Zeller H, Murri S, et al. (2004) Outbreak of West Nile virus causing severe neurological involvement in children, Nuba Mountains, Sudan, 2002. Trop Med Int Health 9: 730-736.
40. Hubalek Z, Halouzka J, (1999) West Nile fever-a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 5: 643-650.
41. Barzon L, Squarzon L, Cattai M, Franchin E, Pagni S, et al. (2009) West Nile virus infection in Veneto region, Italy, 2008-2009. Euro Surveill 14.
42. Campbell GL, Ceianu CS, Savage HM, (2001) Epidemic West Nile encephalitis in Romania: waiting for history to repeat itself. Ann N Y Acad Sci 951: 94-101.
43. Platonov AE, Shipulin GA, Shipulina OY, Tyutyunnik EN, Frolochkina TI, et al. (2001) Outbreak of West Nile virus infection, Volgograd Region, Russia, 1999. Emerg Infect Dis 7: 128-132.
44. Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, et al. (2001) Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 7: 675-678.
45. Hayes EB, Gubler DJ, (2006) West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57: 181-194.
46. Pollard K, (1999) U.S. diversity in more than Black and White. Popul Today 27: 7.
47. Brien JD, Uhrlaub JL, Nikolich-Zugich J, (2007) Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 37: 1855-1863.
48. Lanteri MC, Heitman JW, Owen RE, Busch T, Gefter N, et al. (2008) Comprehensive analysis of west nile virus-specific T cell responses in humans. J Infect Dis 197: 1296-1306.
49. Wang Y, Lobigs M, Lee E, Mullbacher A, (2003) CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77: 13323-13334.
50. t Hart BA, Hintzen RQ, Laman JD, (2009) Multiple sclerosis- a response-to-damage model. Trends Mol Med 15: 235-244.
51. De Rezende PA, Arruda WO, (1996) [Genetic aspects in multiple sclerosis. II: HLA system]. Arq Neuropsiquiatr 54: 439-450.
52. Link J, Lorentzen AR, Kockum I, Duvefelt K, Lie BA, et al. (2010) Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol 226: 172-176.
53. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, et al. (2010) HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 75: 634-640.
54. Lee SI, Kwon HJ, Lee ES, Yang BC, Bang D, et al. (2007) Using pCIN-mIL-4 DNA vector to express mRNA and protein and to improve herpes simplex virus-induced Behcet's disease symptoms in mice. Vaccine 25: 7047-7055.
55. Castillo Palma MJ, Sanchez Roman J, Ocana Medina C, Gonzalez Escribano MF, Nunez Roldan A, et al. (1996) [Serologic and molecular HLA typing in patients from Andalucia with Behcet's disease. Genetic and clinical correlations]. Med Clin (Barc) 106: 121-125.
56. Sanchez Roman J, Castillo Palma MJ, Torronteras Santiago R, Varela Aguilar JM, Lopez Checa F, et al. (1992) [Type I herpes virus, HLA phenotype and Behcet disease]. Med Clin (Barc) 98: 366-368.
57. Abraham A, Ziv S, Drory VE, (2011) Posterior reversible encephalopathy syndrome resulting from guillain-barre-like syndrome secondary to west nile virus infection. J Clin Neuromuscul Dis 12: 113-117.
58. Prydun M, (1983) Guillain-Barre syndrome: disease process. J Neurosurg Nurs 15: 27-32.
59. Koga M, Yuki N, Kashiwase K, Tadokoro K, Juji T, et al. (1998) Guillain-Barre and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J Neuroimmunol 88: 62-66.
60. Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, et al. (1998) HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. Neurology 51: 379-384.
61. Monos DS, Papaioakim M, Ho TW, Li CY, McKhann GM, (1997) Differential distribution of HLA alleles in two forms of Guillain-Barre syndrome. J Infect Dis 176 (Suppl 2): S180-182.
62. Chaturvedi U, Nagar R, Shrivastava R, (2006) Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 47: 155-166.
63. Custer B, Kamel H, Kiely NE, Murphy EL, Busch MP, (2009) Associations between WNV infection and symptoms reported by blood donors identified through nucleic acid test screening. Transfusion 49: 278-288.
64. Luo M, Blanchard J, Brunham K, Pan Y, Shen CX, et al. (2001) Two-step high resolution sequence-based HLA-DRB typing of exon 2 DNA with taxonomy-based sequence analysis allele assignment. Hum Immunol 62: 1294-1310.
65. Luo M, Blanchard J, Pan Y, Brunham K, Brunham RC, (1999) High-resolution sequence typing of HLA-DQA1 and-DQB1 exon 2 DNA with taxonomy-based sequence analysis (TBSA) allele assignment. Tissue Antigens 54: 69-82.
66. Woolf B, (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251-253.